The dengue vaccine, developed after extensive research, now faces hurdles, with reports emerging of possible severe dengue infection occurring in some vaccinated individuals who were previously not exposed to dengue. The dengue vaccine, CYD-TDV (brand name Dengvaxia) was recently approved in 19 countries to protect individuals from dengue infection in the age group of 9 to 45 years, with the hope that it would bring the infection under control in places with high burden of the disease. The vaccine is administered in three doses with a gap of 6 months between doses.
Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer